{"id":543309,"date":"2021-05-14T16:48:01","date_gmt":"2021-05-14T16:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543309"},"modified":"2021-05-14T16:48:01","modified_gmt":"2021-05-14T16:48:01","slug":"oncology-molecular-diagnostics-market-size-worth-usd-35681-million-at-cagr-of-118-by-2027-reports-and-data","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/oncology-molecular-diagnostics-market-size-worth-usd-35681-million-at-cagr-of-118-by-2027-reports-and-data_543309.html","title":{"rendered":"Oncology Molecular Diagnostics Market Size Worth USD 3,568.1 Million at CAGR of 11.8%, By 2027 | Reports and Data."},"content":{"rendered":"
\"Oncology<\/a><\/p>\n
\n
Oncology Molecular Diagnostics Market <\/div>\n<\/div>\n<\/div>\n
Oncology Molecular Diagnostics Market Size \u2013 USD 1,456.6 Million in 2019, Market Growth – CAGR of 11.8%, Market Trends \u2013Increasing awareness about cancer diagnosis at an early stage.<\/div>\n

The rising incidence of cancer is one of the significant factors influencing the oncology molecular diagnostics market growth.<\/strong><\/p>\n

Market Size – USD 1,456.6 Million in 2019, Market Growth – CAGR of 11.8%, Market Trends –Increasing awareness about cancer diagnosis at an early stage.<\/strong><\/p>\n

The global Oncology Molecular Diagnostics Market<\/a> is forecasted to reach USD 3,568.1 Million by 2027, according to a new report by Reports and Data. The oncology molecular diagnostics market is observing high growth due to the rising occurrences of breast cancer across the globe. Breast cancer is the most common type of cancer occurring in women. There were more than 2 million new cases of breast cancer in 2018. Belgium, Luxembourg, and the Netherlands are the countries with the highest rates of occurrences of breast cancer in the year 2018 across the globe. The global survival rates from the disease vary greatly, ranging from around 80% in North America, Japan, and Sweden to nearby 60% in middle-income nations and lower than 40% in low-income nations. Hence, the implementation of molecular breast diagnostics to screen and detect malignant cells in the human breast is driving the growth of the oncology molecular diagnostics market.<\/p>\n

The COVID-19 impact:<\/strong><\/p>\n

The COVID-19 pandemic has made it essential to repurpose the operating rooms for surgeries into intensive care units (ICUs) and pushed hospitals to accommodate patients beyond their full capacity of beds. As a result, in several cases, cancer patients were categorized as non-urgent. Further, the psychological influence of postponed cancer diagnosis as a result of the COVID-19 pandemic cannot be undermined as when psychological, physical, and social health of patients are handled in a positive way, chances of patients’ survival have been seen to improve from a state of illness towards recovering from the disease. COVID-19 has had a significant and negative impact on cancer treatment and research, making a new health emergency for cancer patients’ management a necessity.<\/p>\n

Key participants include Becton, Dickinson, and Company, Danaher Corporation, Roche Diagnostics, Abbott Laboratories, Cepheid, Qiagen NV, Siemens Healthineers, Bayer AG, Dako, and GE Healthcare, among others.<\/strong><\/p>\n

Get a sample of the report @ <\/strong>https:\/\/www.reportsanddata.com\/sample-enquiry-form\/3714<\/a><\/p>\n

Further key findings from the report suggest<\/strong><\/p>\n